Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry.

BACKGROUND The importance of statins in cardiovascular prevention has been demonstrated in various patient subsets. This study aimed to evaluate the effects of statins on long-term outcomes of Japanese patients undergoing their first coronary revascularization. METHODS AND RESULTS A total of 9,225 patients undergoing their first coronary revascularizations during 2000--2002 were divided into 2 groups according to the use of statins at discharge; patients with acute myocardial infarction were not included. Statins was administered to only 28.5% (n=2,630) of the patients. The median follow-up period was 3.5 years. Patients on statin therapy showed lower all-cause (5.2% vs 10.0%; p<0.0001) and cardiovascular (3.2% vs 6.2%; p<0.0001) mortality than those without statins (n=6,595) by Kaplan-Meier analysis and log-rank test. After adjustment by multivariate analysis according to 29 variables, statin therapy remained as an independent predictor of reduced all-cause (relative risk ratio (RR) 0.71, 95% confidence interval (CI) 0.59-0.86, p=0.0005) and cardiovascular (RR 0.72, 95% CI 0.56-0.91, p=0.0067) mortality. The validity of RR of statin therapy in multivariate analysis was further confirmed by risk adjustment using propensity scores (all-cause mortality: propensity-adjusted RR 0.70, 95% CI 0.58-0.85, p=0.0003; cardiovascular mortality: propensity-adjusted RR 0.70, 95% CI 0.54-0.89, p=0.0038). CONCLUSIONS Statin therapy started at hospital discharge was associated with increased chance of survival in Japanese patients undergoing their first coronary revascularization.

[1]  C. Molina,et al.  Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator , 2007, Stroke.

[2]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[3]  L. Kuller,et al.  Coronary heart disease mortality among men aged 35-44 years by prefecture in Japan in 1995-1999 compared with that among white men aged 35-44 by state in the United States in 1995-1998: vital statistics data in recent birth cohort. , 2001, Japanese circulation journal.

[4]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[5]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[6]  R. Mongiardo,et al.  Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. , 2000, Circulation.

[7]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[8]  P. Libby,et al.  Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study , 2004, Circulation.

[9]  L. Kuller,et al.  Coronary Heart Disease Mortality Among Men Aged 35-44 Years by Prefecture in Japan in 1995-1999 Compared With That Among White Men Aged 35-44 by State in the United States in 1995-1998 , 2001 .

[10]  E. Topol,et al.  Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features , 2004, Circulation.

[11]  A. Go,et al.  Statin and -Blocker Therapy and the Initial Presentation of Coronary Heart Disease , 2006, Annals of Internal Medicine.

[12]  M. Hori,et al.  Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[13]  R. Nagai,et al.  Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[14]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[15]  H. Shimomura,et al.  Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.

[16]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[17]  L. Kuller,et al.  Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. , 2007, American journal of epidemiology.

[18]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[19]  A. Go,et al.  Statin and beta-blocker therapy and the initial presentation of coronary heart disease. , 2006, Annals of internal medicine.

[20]  S. Ogawa,et al.  Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[21]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[22]  W. Vaughn,et al.  Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery , 2004, Circulation.

[23]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[24]  G. Reeder,et al.  Modern adjunctive pharmacotherapy of myocardial infarction , 2000, Expert opinion on pharmacotherapy.

[25]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[26]  Patrick W Serruys,et al.  Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. , 2005, Journal of the American College of Cardiology.

[27]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[28]  N. Hagiwara,et al.  Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). , 2007, The American journal of cardiology.

[29]  B. Gersh.  Effect of Statin Use Within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortality , 2006 .

[30]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.

[31]  Takeshi Kimura,et al.  Long-Term Outcomes of Coronary-Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease in the Bare-Metal Stent Era , 2008, Circulation.

[32]  D. Krieger,et al.  Statin Use is Independently Associated with Smaller Infarct Volume in Nonlacunar MCA Territory Stroke , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[33]  N. Curzen,et al.  Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? , 2005, Postgraduate Medical Journal.

[34]  L. Tavazzi,et al.  The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. , 2005, European heart journal.

[35]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[36]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[37]  J. Probstfield,et al.  Cardioprotective Strategies to Improve Long‐Term Outcomes Following Coronary Artery Bypass Surgery , 2006, Journal of cardiac surgery.

[38]  Wei Dong,et al.  Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. , 2005, The American journal of cardiology.

[39]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[40]  S. Grundy,et al.  Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study , 2006, The Lancet.

[41]  B. Davis,et al.  Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. , 1999, Journal of the American College of Cardiology.

[42]  A. Kastrati,et al.  Statin treatment following coronary artery stenting and one-year survival. , 2002, Journal of the American College of Cardiology.